Immunic Therapeutics

?? Join Immunic's CEO, Dr. Daniel Vitt, for a company presentation at the ???????? ???????????????? ???????????? ???????????????on ??? Thursday, November 21, 2024 at 1:00 pm ET. Get an exclusive overview of our company, development pipeline and upcoming milestones. Registration here:??? https://bit.ly/4fxmXoH #IMUX #Immunic #InvestorSummit

???Immunic’s Dr. Indira Pichetto Olanda, Associate Medical Manager, will be participating in the ?????? ?????????? ???????????????? ?????????????????? ???? ???????????? ?????????????? ???????? taking place November 20-21 in ???? Buenos Aires, Argentina. This event, also known as the "Simposio Latinoamericano Enfermedad Celiaca 2024," gathers global experts to discuss advances in celiac disease research. We look forward to insightful discussions and new connections! #ISSCD #LASSCD ISSCD #IMU856 #Celiac #CeliacDisease #IMUX #Immunic

?? Don't miss this insightful interview in Authority Magazine with our CEO, Dr. Daniel Vitt, discussing his passion for drug development, science and leadership, as well as how Immunic aims to revolutionize the treatment of multiple sclerosis! ?? Learn more about Daniel’s vision here: ?? https://bit.ly/3CJX2LW #Immunic #IMUX #MulitpleSclerosis #MS #vidofludimus #IMU838

???? London calling! ???? ??Meet Immunic’s management, business development and investor relations teams in London, UK, this week. We are hosting one-on-one meetings in connection with the Jefferies Healthcare Conference 2024. ??To schedule a last minute meeting, please contact Jessica Breu, VP Investor Relations & Communications! See you around! Daniel Vitt, Jason Tardio, Patrick Walsh #Jefferies #Immunic #IMUX #InvestorRelations #BusinessDevelopment #Partnering #Networking #Biotech #Healthcare #London

?? Publication Alert: ?????? ???????????? ???????????????????????????????? & ????????????????????! Dr. Andreas Muehler, Immunic’s Chief Medical Officer, shared insights on our phase 1/1b clinical trial results with Proactive’s Stephen Gunnion, underscoring the significance of this data set and its publication in such a prestigious journal. ? https://bit.ly/3UQ4pYw IMU-856 has shown promising potential as a once-daily oral treatment for celiac disease—a condition still in high need of effective treatment options. Don't miss the full discussion with Dr. Muehler about IMU-856’s future potential across gastrointestinal diseases! The Lancet #Gastroenterology #Celiac #CeliacDisease #IMU856 #Immunic #IMUX

?? Next week, Immunic's management, business development, and investor relations teams will be in London, hosting one-on-one meetings around the Jefferies London Healthcare Conference 2024. This will be a great opportunity to connect with us, discuss our latest developments and explore potential cooperations! To schedule a meeting, please reach out to Jessica Breu, Vice President Investor Relations and Communications. Daniel Vitt, Jason Tardio, #Jefferies #Immunic #IMUX #InvestorRelations #BusinessDevelopment #Partnering #Networking #Biotech #Healthcare

?? Data on Immunic's drug candidate in celiac disease published in ?????? ???????????? ???????????????????????????????? & ????????????????????! ?? We are pleased to share that our phase 1 data in healthy human subjects and phase 1b data in patients with celiac disease from our clinical trial of IMU-856 has been published in this prestigious peer reviewed journal. ? https://bit.ly/3AFIX1w The article around lead author, Dr. A. James Daveson, Gastroenterologist, Wesley Research Institute and Coral Sea Clinical Research Institute, Queensland, Australia provides insights into IMU-856’s phase 1 clinical profile and its potential to support gut health and restore barrier function – key challenges in celiac disease. The Lancet #Immunic #IMUX #Gastroenterology #CeliacDisease #Celiac #IMU856

Curious how Immunic is tackling the fight against multiple sclerosis? ?? Our recent interim analysis confirmed that our phase 3 ENSURE trials can continue as planned, bringing us one step closer to a potential new treatment option with a unique dual mode of action. Vidofludimus calcium not only has anti-inflammatory and antiviral effects, but it also has the potential to address significant unmet medical needs in neuroprotection. Discover more in BioWorld News's latest article: ?? https://bit.ly/3NHoTid #MS #MultipleScerlosis #PMS #RMS #MSResearch #Vidofludimus #ENSURE #ClinicalTrials #Biotech #Immunic #IMUX

???Dive into the details of our Q3/2024 earnings update and get the latest company news from our CEO, Dr. Daniel Vitt. Check out his most recent interview with Proactive to catch all the highlights! ?? https://bit.ly/3AEmEcB #proactive #IMUX #Immunic #Biotechnology #FinancialReporting #FinancialResults

?? Join us today until November 9 at the ?????????????????? ??????: ????????????-???????????????? ???????????????? ???? ?????? ???? ??????????: ?????????? ???? ???? ??????????? in Florence,???? Italy. Sara Elhag, PhD Elhag, Ph.D., Immunic's Associate Manager Translational Pharmacology, will present a poster on the very encouraging data from our phase 1b clinical trial of IMU-856 in celiac disease. ?? Falk Foundation #Celiac #CeliacDisease #IMU856 #Gastroenterology #IMUX #Immunic